AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9527356 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet containing 0.55 mg NaF
Number of subjects: 24
Study 9527356 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial fluoride toothpicks and dental flosses
Number of subjects: 24
Study 9527356 — intervention group
Group type: COMPARATOR
Intervention: Sampling procedure
Number of subjects: 24
Study 7837388 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential regimen (four courses of doxorubicin followed by eight courses of CMF)
Number of subjects: 403
Study 7837388 — intervention group
Group type: COMPARATOR
Intervention: Alternating regimen (two courses of CMF alternated with one course of doxorubicin)
Number of subjects: 403
Study 2297344 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (n = 23)
Number of subjects: 40
Study 2297344 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (n = 17)
Number of subjects: 40
Study 694481 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/d tamoxifen by mouth
Number of subjects: 158
Study 694481 — intervention group
Group type: EXPERIMENTAL
Intervention: tamoxifen
Number of subjects: 158
Study 31722650 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative cognitive-behavioral therapy (25 ± 3 sessions)
Number of subjects: 47
Study 30853500 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Start Denver Model (ESDM), an intensive, naturalistic developmental‐behavioural intervention program
Number of subjects: 48
Study 28317510 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-step facilitation (TSF) intervention: Stimulant Abuser Groups to Engage in 12-Step (STAGE-12)
Number of subjects: 471
Study 28317510 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 471
Study 23929521 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion Management Training (EMT)
Number of subjects: 72
Study 23929521 — intervention group
Group type: COMPARATOR
Intervention: Social Skills Training (SST)
Number of subjects: 72
Study 23929521 — intervention group
Group type: COMPARATOR
Intervention: No Treatment
Number of subjects: 72
Study 23958293 — intervention group
Group type: EXPERIMENTAL
Intervention: PIVOT technique (interleaved pulsed arterial spin labeling and multi-echo gradient-recalled echo sequences)
Number of subjects: 10
Study 23958293 — intervention group
Group type: EXPERIMENTAL
Intervention: PIVOT technique
Number of subjects: 10
Study 21869685 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon 8 mg/d
Number of subjects: 25
Study 21869685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 19628206 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 microg of sublingual misoprostol
Number of subjects: 300
Study 19628206 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg of sublingual misoprostol
Number of subjects: 300
Study 19628206 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous oxytocin
Number of subjects: 300
Study 19628206 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylergometrine
Number of subjects: 300
Study 19628206 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol groups
Number of subjects: 300
Study 19628206 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylergometrine group
Number of subjects: 300
Study 19628206 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 300
Study 17255231 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine alone
Number of subjects: 0
Study 17255231 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine plus albendazole
Number of subjects: 0
Study 17255231 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine
Number of subjects: 0
Study 15482083 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption cue
Number of subjects: 40
Study 15482083 — intervention group
Group type: COMPARATOR
Intervention: No-consumption cue
Number of subjects: 40
Study 11678862 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (MT) 10 mg once a day
Number of subjects: 51
Study 11678862 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine (CET) 10 mg once a day
Number of subjects: 51
Study 11678862 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 51
Study 9759273 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous epinephrine, 10 micrograms/kg (n = 28)
Number of subjects: 54
Study 9759273 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous terbutaline, 10 micrograms/kg (n = 26)
Number of subjects: 54
Study 7840862 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 41
Study 7840862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 2894359 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam (DA1 receptor agonist)
Number of subjects: 10
Study 29351130 — intervention group
Group type: COMPARATOR
Intervention: Aerobic moderate-intensity cycling (AMC)
Number of subjects: 28
Study 29351130 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume time-based resistance exercise training (TRE)
Number of subjects: 28
Study 27582175 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Management Review (MMR) service
Number of subjects: 160
Study 27582175 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MMR service)
Number of subjects: 160
Study 23913094 — intervention group
Group type: EXPERIMENTAL
Intervention: Thulium laser resection of the prostate-tangerine technique (TmLRP-TT)
Number of subjects: 96
Study 23913094 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of prostate (TURP)
Number of subjects: 96
Study 23334802 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuff pressure maintained at approximately 25 cm H2O throughout the operation (Group B)
Number of subjects: 90
Study 23334802 — intervention group
Group type: COMPARATOR
Intervention: Cuff pressure set to 25 cm H2O initially and monitored continuously without adjustment (Group A)
Number of subjects: 90
Study 23334802 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 90
Study 20600478 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03(B)-adjuvanted vaccine (1.9microg HA)
Number of subjects: 157
Study 20600478 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03(A)-adjuvanted vaccine (3.75microg HA)
Number of subjects: 157
Study 18975322 — intervention group
Group type: EXPERIMENTAL
Intervention: R788 100 mg
Number of subjects: 189
Study 18975322 — intervention group
Group type: EXPERIMENTAL
Intervention: R788 150 mg
Number of subjects: 189
Study 18975322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study 18975322 — intervention group
Group type: COMPARATOR
Intervention: R788 50 mg
Number of subjects: 189
Study 16021197 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser peripheral iridoplasty (ALPI)
Number of subjects: 77
Study 16021197 — intervention group
Group type: COMPARATOR
Intervention: Systemic medications (acetazolamide +/- mannitol)
Number of subjects: 77
Study 14980092 — intervention group
Group type: EXPERIMENTAL
Intervention: Teledermatology consultation
Number of subjects: 0
Study 14980092 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 11351768 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (25 mg b.d.)
Number of subjects: 6602
Study 11351768 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (400 mg b.d.)
Number of subjects: 6602
Study 11351768 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of aspirin and dipyridamole
Number of subjects: 6602
Study 11351768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6602
Study 9197296 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil by computer-controlled infusion
Number of subjects: 46
Study 9197296 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (25 mg)
Number of subjects: 46
Study 9197296 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (25 mg) plus Alfentanil
Number of subjects: 46
Study 9197296 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (4 mg)
Number of subjects: 46
Study 1566090 — intervention group
Group type: EXPERIMENTAL
Intervention: PU gravity-drainage systems
Number of subjects: 56
Study 1566090 — intervention group
Group type: COMPARATOR
Intervention: PVC (Redon) drainage systems
Number of subjects: 56
Study 3916837 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (60 mg daily for the first month, 120 mg daily for the second and third months)
Number of subjects: 15
Study 3916837 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 15
Study 31597650 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment-based compassion therapy (ABCT)
Number of subjects: 90
Study 31597650 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted mindfulness-based stress reduction (MBSR)
Number of subjects: 90
Study 31597650 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 90
Study 28520666 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger Self-Management Training (ASMT)
Number of subjects: 90
Study 28520666 — intervention group
Group type: COMPARATOR
Intervention: Personal Readjustment and Education (PRE)
Number of subjects: 90
Study 25749495 — intervention group
Group type: COMPARATOR
Intervention: Non-respiratory physiotherapist treatments
Number of subjects: 93
Study 25749495 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory physiotherapist treatments
Number of subjects: 93
Study 22777853 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenodesis of the extensor carpi ulnaris
Number of subjects: 0
Study 22777853 — intervention group
Group type: COMPARATOR
Intervention: No tenodesis of the extensor carpi ulnaris (Control)
Number of subjects: 0
Study 21153660 — intervention group
Group type: EXPERIMENTAL
Intervention: 55% VO₂(max)
Number of subjects: 0
Study 21153660 — intervention group
Group type: EXPERIMENTAL
Intervention: 75% VO₂(max)
Number of subjects: 0
Study 21153660 — intervention group
Group type: EXPERIMENTAL
Intervention: Both exercise intensities (I1 and I2)
Number of subjects: 0
Study 19015858 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field (PEMF) therapy
Number of subjects: 55
Study 19015858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 17383818 — intervention group
Group type: EXPERIMENTAL
Intervention: SRT plus specific cognitive exercise
Number of subjects: 50
Study 17383818 — intervention group
Group type: COMPARATOR
Intervention: SRT (placebo)
Number of subjects: 50
Study 12574184 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg/d
Number of subjects: 40
Study 12574184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10477245 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet high in synthetic triglycerides of stearic acid (18:0) for four weeks
Number of subjects: 18
Study 10477245 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet high in synthetic triglycerides of palmitic acid (16:0) for four weeks
Number of subjects: 18
Study 10477245 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet high in synthetic triglycerides of myristic acid (14:0) for four weeks
Number of subjects: 18
Study 10477245 — intervention group
Group type: COMPARATOR
Intervention: Baseline diet providing 11 energy (en)% saturated fat
Number of subjects: 18
Study 8692531 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical bacillus Calmette‐Guérin (BCG)
Number of subjects: 132
Study 8692531 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin
Number of subjects: 132
Study 1762975 — intervention group
Group type: EXPERIMENTAL
Intervention: Transparent adherent dressing (TAD) changed every four days
Number of subjects: 98
Study 1762975 — intervention group
Group type: COMPARATOR
Intervention: Dry sterile gauze dressing (DSGD) changed daily
Number of subjects: 98
Study 6754845 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-exposure immune serum globulin
Number of subjects: 23447
Study 6754845 — intervention group
Group type: COMPARATOR
Intervention: Non-immunised group (control)
Number of subjects: 23447
Study 6323376 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 25
Study 6323376 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin/Chloramphenicol
Number of subjects: 25
Study 29313186 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystemic Therapy (MST)
Number of subjects: 697
Study 29313186 — intervention group
Group type: COMPARATOR
Intervention: Functional Family Therapy (FFT)
Number of subjects: 697
Study 26461811 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-scale community and school-level interventions promoting handwashing with soap
Number of subjects: 0
Study 26461811 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 24885844 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management group intervention (10 hours total, facilitated group workshop sessions)
Number of subjects: 300
Study 24885844 — intervention group
Group type: COMPARATOR
Intervention: No-treatment (wait list) control condition
Number of subjects: 300
Study 22403699 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 3134
Study 22403699 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody (mAb) immunotherapy
Number of subjects: 3134
Study 22403699 — intervention group
Group type: COMPARATOR
Intervention: Vaccine subgroup
Number of subjects: 3134
Study 22403699 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine immunotherapy
Number of subjects: 3134
Study 22403699 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3134
Study 20332358 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 1.25 microg
Number of subjects: 8
Study 20332358 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 2.5 microg
Number of subjects: 8
Study 20332358 — intervention group
Group type: COMPARATOR
Intervention: Insulin monotherapy
Number of subjects: 8
Study 18759643 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (RIS)
Number of subjects: 232
Study 18759643 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 232
Study 15969642 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% dorzolamide/0.5% timolol combination eye drops twice daily
Number of subjects: 544
Study 15969642 — intervention group
Group type: COMPARATOR
Intervention: 0.005% latanoprost eye drops once daily
Number of subjects: 544
Study 14506621 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 16
Study 10385131 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate gel forming solution 0.5% (Timoptic‐XE)
Number of subjects: 14
Study 10385131 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol hemihydrate 0.5% (Betimol)
Number of subjects: 14
Study 10385131 — intervention group
Group type: COMPARATOR
Intervention: Placebo (HypoTears)
Number of subjects: 14
Study 8895240 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline iontophoresis in untreated skin
Number of subjects: 13
Study 8895240 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline iontophoresis in capsaicin-treated skin
Number of subjects: 13
Study 8895240 — intervention group
Group type: COMPARATOR
Intervention: Cuff pressure of 200 mmHg in capsaicin-treated skin
Number of subjects: 13
Study 8895240 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline during arterial occlusion in capsaicin-treated skin
Number of subjects: 13
Study 8895240 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline during arterial occlusion in untreated skin
Number of subjects: 13
Study 8895240 — intervention group
Group type: COMPARATOR
Intervention: Reactive hyperaemia after cuff pressure release in capsaicin-treated skin
Number of subjects: 13
Study 8895240 — intervention group
Group type: COMPARATOR
Intervention: Reactive hyperaemia after cuff pressure release in untreated skin
Number of subjects: 13
Study 1476282 — intervention group
Group type: COMPARATOR
Intervention: albumin 4%
Number of subjects: 60
Study 1476282 — intervention group
Group type: COMPARATOR
Intervention: dextran 40 3.5%
Number of subjects: 60
Study 1476282 — intervention group
Group type: EXPERIMENTAL
Intervention: dextran 60 6%
Number of subjects: 60
Study 1476282 — intervention group
Group type: EXPERIMENTAL
Intervention: hydroxyethylstarch (HES) 200 6%
Number of subjects: 60
Study 1476282 — intervention group
Group type: EXPERIMENTAL
Intervention: modified fluid gelatin
Number of subjects: 60
Study 1476282 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer lactate
Number of subjects: 60
Study 6304203 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (200 mg/m2 per day for two weeks)
Number of subjects: 56
Study 6304203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 31542730 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition team
Number of subjects: 105
Study 28408059 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAAs + HPHF diet (1.2g/kg protein, 30g fiber, 110g BCAAs daily)
Number of subjects: 72
Study 28408059 — intervention group
Group type: COMPARATOR
Intervention: HPHF diet (1.2g/kg protein, 30g fiber)
Number of subjects: 72
Study 28408059 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAAs + HPHF diet
Number of subjects: 72
Study 28408059 — intervention group
Group type: COMPARATOR
Intervention: HPHF diet
Number of subjects: 72
Study 27035404 — intervention group
Group type: EXPERIMENTAL
Intervention: L-methylfolate calcium 15 mg
Number of subjects: 68
Study 24527996 — intervention group
Group type: EXPERIMENTAL
Intervention: mTBIMVA vignette
Number of subjects: 244
Study 24527996 — intervention group
Group type: COMPARATOR
Intervention: mTBIsport vignette
Number of subjects: 244
Study 24527996 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal knowledge of mTBI
Number of subjects: 244
Study 22404241 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA) with levobupivacaine, ketorolac, and epinephrine
Number of subjects: 60
Study 22404241 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal morphine (it‐M) 0.1 mg
Number of subjects: 60
Study 22404241 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA)
Number of subjects: 60
Study 22404241 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal morphine (it‐M)
Number of subjects: 60
Study 20537376 — intervention group
Group type: EXPERIMENTAL
Intervention: ART initiated
Number of subjects: 3381
Study 20537376 — intervention group
Group type: COMPARATOR
Intervention: No ART
Number of subjects: 3381
Study 20537376 — intervention group
Group type: COMPARATOR
Intervention: No ART with CD4 < 200 cells per microL
Number of subjects: 3381
Study 20537376 — intervention group
Group type: COMPARATOR
Intervention: No ART with CD4 > 200 cells per microL
Number of subjects: 3381
Study 17031691 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (50 mg/kg/day)
Number of subjects: 30
Study 16198779 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 37
Study 16198779 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus ointment 0.1%
Number of subjects: 37
Study 16198779 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 37
Study 16198779 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus
Number of subjects: 37
Study 15538055 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated PCI with thrombolytic therapy plus glycoprotein IIb/IIIa inhibitor
Number of subjects: 0
Study 15538055 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated PCI with glycoprotein IIb/IIIa inhibitor alone
Number of subjects: 0
Study 15538055 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated PCI with thrombolytic therapy
Number of subjects: 0
Study 15538055 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated PCI (general)
Number of subjects: 0
Study 10365803 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin (800 mg/day) plus leucocytic interferon-alpha (3 mega units thrice weekly)
Number of subjects: 50
Study 10365803 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha alone (3 mega units thrice weekly)
Number of subjects: 50
Study 8523983 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine-needle aspiration
Number of subjects: 0
Study 8523983 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine-needle capillary biopsy
Number of subjects: 0
Study 8523983 — intervention group
Group type: COMPARATOR
Intervention: Both techniques
Number of subjects: 0
Study 1851191 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (6 mg)
Number of subjects: 19
Study 1851191 — intervention group
Group type: COMPARATOR
Intervention: Control (no nedocromil sodium)
Number of subjects: 19
Study 7012996 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacampicillin (800 mg twice a day)
Number of subjects: 77
Study 7012996 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin (500 mg three times a day)
Number of subjects: 77
Study 31056956 — intervention group
Group type: EXPERIMENTAL
Intervention: Food insecurity status assessment using the 10-item US Household Food Security Scale Module
Number of subjects: 398
Study 31056956 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with food insecurity
Number of subjects: 398
Study 31056956 — intervention group
Group type: EXPERIMENTAL
Intervention: Father's occupation as a farmer
Number of subjects: 398
Study 31056956 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother's occupation as a farmer
Number of subjects: 398
Study 27903520 — intervention group
Group type: COMPARATOR
Intervention: Low-fat, high-carbohydrate (LFHC) diet (30% of energy fat and 53% of energy carbohydrate)
Number of subjects: 46
Study 27903520 — intervention group
Group type: EXPERIMENTAL
Intervention: Very high-fat, low-carbohydrate (VHFLC) diet (73% of energy fat and 10% of energy carbohydrate)
Number of subjects: 46
Study 26360740 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic floppy Nissen fundoplication (LNF)
Number of subjects: 84
Study 26360740 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic Toupet fundoplication (LTF)
Number of subjects: 84
Study 24214585 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pantoprazole (initial dose 40 mg, then 40 mg every 12 hours for 3 days, followed by 40 mg orally)
Number of subjects: 89